CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages

Table 2

Comparison of HE4, CA125, ROMA, and CPH-I in different groups.

	Benign			BOT I+II			EOC I+II
	All	Pre-M	Post-M	All	Pre-M	Post-M	All	Pre-M	Post-M
HE4 (pmol/L)	43.8 (39.2-49.1)	43.9 (38.9-49.1)	43.5 (41.5-55.9)	48.4 (41.8-56.5)	47.6 (41.2-56.0)	50.1 (45.4-61.4)	80.3 (55.3-171.2)^^	64.2 (50.7-136.4)^^	95.0 (67.4-221.0)^^
CA125 (U/mL)	24.9 (15.2-55.0)	25.3 (16.2-61.0)	13.6 (10.5-33.7)	34.1 (19.5-69.0)	35.6 (21.5-67.3)^#	22.2 (16.9-189.8)	95.1 (35.6-234.5)^^	88.5 (35.7-182.1)^^	104.5 (33.4-320.7)
ROMA (%)	6.03 (4.5-8.0)	5.7 (4.4-7.4)	11.5 (8.1-16.5)	7.5 (5.3-12.0)	6.7 (5.1-10.3)	15.4 (11.7-56.5)	30.7 (10.6-65.6)^^	14.6 (8.7-49.5)^^	59.7 (28.6-81.5)^^
CPH-I (%)	1.0 (0.7-2.3)	1.0 (0.7-2.2)	1.8 (0.9-2.5)	1.6 (0.9-3.1)	1.4 (0.9-2.8)^#	2.3 (1.4-16.1)	11.3 (3.3-42.6)^^	7.2 (2.3-26.0)^^	25.1 (7.4-59.9)^^

Note: data are presented as the median (interquartile range). and ^# compared with benign corresponding subgroups; ^{^} compared with BOT I+II corresponding subgroups. Abbreviations: Pre-M = premenopausal; Post-M = postmenopausal; BOT I+II = borderline ovarian tumors in FIGO stages I and II; EOC I+II = epithelial ovarian cancer in FIGO stages I and II.